X-Chem announces strategic collaboration with Astellas Pharma across multiple therapeutic areas.
X-Chem, Inc., a privately held biotechnology company applying its drug discovery capabilities to the generation of novel small molecule therapeutics, announced the signing of a broad drug discovery collaboration with Astellas Pharma Inc. The collaboration will enable the discovery of novel lead compounds for complex drug targets of interest to Astellas from X-Chem’s growing collection of DNA-encoded DEX libraries containing over 120 billion compounds.
The new partnership is X-Chem’s most expansive first-time alliance with a pharmaceutical company, and is aimed at tackling hard-to-drug targets across multiple therapeutic areas at Astellas.
“We are delighted to enter into a long-term relationship with a partner of the caliber of Astellas,” said Rick Wagner, Ph.D., Chief Executive Officer of X-Chem. “Our agreement is structured as a highly collaborative effort that has the potential to both be a leading source of new chemical entities into Astellas’ future portfolio and make a meaningful impact on the treatment of human diseases.”
Under the terms of this multi-year agreement, X-Chem will receive an up-front payment of $16 million. X-Chem is eligible to receive research funding, as well as license and option fees as the drug discovery collaboration proceeds. Additionally, Astellas has the option to license compounds identified through this collaboration, and X-Chem will be entitled to pre-clinical, developmental, and commercial milestone payments on licensed compounds against each target. Milestone payments could amount to over $100 million per target, in addition to royalties based on sales of future products.
“This is a transformational deal for X-Chem in terms of its scope and duration,” said O. Prem Das, Ph.D., Executive, Business Development at X-Chem. “It is customized to meet Astellas’ needs in generating novel lead structures against new and difficult targets. The transaction includes built-in mechanisms to expand the research scope, and enables increasing involvement and input of Astellas scientists in the DEX-based discovery process over time.”
The DNA-Encoded X-Chem (DEX) Library and Platform
Due to the size and diversity of the DEX library, X-Chem can discover multiple series of novel, potent and selective lead compounds at an unprecedented rate of success against a wide range of targets, including some that previously failed using conventional screening methods. A number of proprietary innovations in library design, screening methodology and bioinformatics underlie the performance of the DEX platform. In particular, X-Chem’s approach to library construction allows for additional chemical reactions to become useable in DNA-encoded library synthesis.
Together, these developments result in a much greater repertoire of diversity for small molecules, which cover a range of categories including fragment molecules, small molecular weight heterocyclic compounds, and macrocyclic structures. This diverse library, combined with a heightened ability to detect active molecules, has yielded a robust process that has been highly successful against targets categorized as difficult or intractable, according to th company
(Source: Business Wire)
Filed Under: Drug Discovery